Mandy Moore Goes Viral After Heartfelt Social Media Post—Here’s Why Everyone’s Talking

Actress and singer Mandy Moore is turning a frightening chapter in her parenting journey into a public health mission, teaming up with Sanofi to spotlight RSV prevention after both of her young sons contracted the respiratory virus in 2023. Moore told People that watching August “Gus” Harrison, 4, and Oscar “Ozzie” Bennett, 3, struggle with the illness left her feeling “super helpless,” even though neither child required hospitalization. The scare motivated the 41-year-old This Is Us star to seek stronger protection for her third baby, daughter Louise “Lou” Everett, born last September. On her pediatrician’s recommendation, Lou received Beyfortus (nirsevimab-alip) on Oct. 1—the first day the long-acting antibody became available for infants entering RSV season. Now Moore has joined Sanofi’s new “Mom Squad” alongside journalist Elaine Welteroth, chef Gaby Dalkin, astronaut Katya Echazarreta and Olympic gymnast Shawn Johnson East. The celebrity moms are sharing personal RSV stories to raise awareness of Beyfortus, the first monoclonal antibody approved for all babies—full-term or pre-term, healthy or high-risk—through their first RSV season. Why RSV Matters for Parents • RSV is the leading cause of infant hospitalization in the United States. • Two out of three babies catch RSV before their first birthday, and nearly all children contract it by age two. • Symptoms often mimic a common cold at first but can quickly progress to bronchiolitis or pneumonia. What Is Beyfortus? Beyfortus is a single-dose, long-acting antibody that delivers fast passive immunity lasting roughly five months—the length of a typical RSV season. Clinical and real-world data covering more than 400,000 infants show an 87 percent reduction in RSV-related hospital and doctor visits, according to Sanofi. Moore’s Prevention Playbook • Consult early: Moore spoke to pediatrician Dr. Danny Bruckner while still pregnant with Lou to plan RSV protection. • Time the dose: Infants can receive Beyfortus before or during RSV season; children up to 24 months at continued risk qualify for an additional dose. • Lean on community: “Nobody gets it like another mom,” Moore says, crediting her Mom Squad for support. The Bigger Picture for Baby Health Moore’s advocacy arrives as pediatric offices prepare for the 2025-26 RSV season. Parents are urged to ask their child’s doctor about eligibility, potential side effects (rash or injection-site pain are most common) and how Beyfortus compares with older, monthly options such as palivizumab. Key Takeaways • Mandy Moore turns personal RSV scare into nationwide awareness campaign. • Sanofi’s Beyfortus offers single-dose protection for virtually all infants. • Early consultation with healthcare providers can help parents navigate RSV season confidently. For more on Mandy Moore’s partnership and real-time RSV guidance, visit Beyfortus.com or speak with your pediatrician today.